Actively Recruiting
Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies
Led by Xinqiao Hospital of Chongqing · Updated on 2026-01-20
47
Participants Needed
1
Research Sites
158 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Malignant hematological tumors mainly derived from adult B cells are mainly acute lymphoblastic leukemia (ALL) and non Hodgkin lymphoma (NHL). Overall, although existing therapies have significantly improved the survival rates of most patients, the treatment of relapsed/refractory patients still faces significant challenges. CD19 is one of the most clinically valuable targets for B-cell malignant hematological tumors. The advent of COVID-19 vaccine has brought LNP mRNA technology into the public's view. After years of development, it not only shines brilliantly in COVID-19 vaccine, but also is widely used in the treatment and exploration of cancer, rare diseases and other fields. Lipid nanoparticles (LNP) are currently the most mature non viral delivery platform, capable of protecting mRNA from nuclease degradation, promoting intracellular uptake, and achieving efficient translation in vivo. The core of LNP-mRNA technology targeting CD19 is to encapsulate the mRNA encoding specific proteins (such as anti-CD19 related proteins) in lipid nanoparticles and deliver them to the body through intravenous or intramuscular injection.
CONDITIONS
Official Title
Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 70 years
- Expected survival longer than 12 weeks
- Diagnosed with CD19-positive B-cell lymphoma or lymphocytic leukemia with no standard treatment options
- Assessable lesions present (for lymphoma patients)
- Eastern Cancer Collaboration Group (ECOG) physical fitness score of 0 or 1
You will not qualify if you...
- Presence of other uncontrolled malignant tumors
- Previous treatment with CAR-T or other transgenic T cell therapies
- Known HIV infection or active hepatitis B or C infection
- History of central nervous system lymphoma, malignant cells in cerebrospinal fluid, or brain metastases
- Any other condition deemed unsuitable by the researcher for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Hematology, Xinqiao Hospital
Chongqing, Chongqing Municipality, China, 400037
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here